Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Blood (2023) 142 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2023-180485

Published: 2023

Journal Articles

Addition of Chidamide to a Sandwich Protocol, Pegaspargase, Gemcitabine and Oxaliplatin Chemotherapy Combined with Radiotherapy, As First-Line Treatment in Early Stage NK/T-Cell Lymphoma: Real World Outcomes in a Retrospective Study

Fan Xia, Nana Ping, Qi Bao, Rui Zou, Qian Zhu, Xiao Zhang, Depei Wu, Zhengming Jin, Changju Qu

Blood (2023) 142 (Supplement 1): 6202.

https://doi.org/10.1182/blood-2023-177828

Published: 2023

Journal Articles

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Miao Hu, Xinglu Zhou, Jie Jin

Blood (2023) 142 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2023-185363

Published: 2023

Journal Articles

Zr Study: A Prospective Phase II Study of Zanubrutinib-Rituximab Chemo-Free Therapy with or without Autologous Stem Cell Transplantation in Newly Diagnosed Mantle Cell Lymphoma

Changju Qu, Nana Ping, Rui Zou, Jiajie He, Qian Zhu, Xiao Zhang, Fan Xia, Danqing Kong, Depei Wu, Zhengming Jin

Blood (2023) 142 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2023-179599

Published: 2023

Journal Articles

Survival Outcome of Autologous or Allogeneic Stem Cell Transplantation in 49 Patients with Extranodal NK/T-Cell Lymphoma

Mao Jin, Sicheng Ai, Tao You, Xiao Ma, Feng Chen, Caixia Li, Zhengming Jin, Depei Wu, Haiwen Huang

Blood (2023) 142 (Supplement 1): 6215.

https://doi.org/10.1182/blood-2023-186001

Published: 2023

Journal Articles

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2023-180694

Published: 2023

Journal Articles

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Sining Liu, Qingya Cui, Zheng Li, Wei Cui, Mengyun Li, Huiying Qiu, Shengli Xue, Suning Chen, Zhengming Jin, Miao Miao, Yue Han, Ying Wang, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2023-186718

Published: 2023

Journal Articles

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Xuanqi Cao, Zheng Li, Yanming Zhang, Qingya Cui, Yunju Ma, Mengyun Li, Sifan Chen, Jia Yin, Wei Cui, Jia Chen, Aining Sun, Huiying Qiu, Suning Chen, Zhengming Jin, Xiaming Zhu, De-Pei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6959.

https://doi.org/10.1182/blood-2023-185258

Published: 2023

Journal Articles

Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Preliminary Results from a Phase II Study

Nana Ping, Changju Qu, Jiajie He, Hailing Liu, Rui Zou, Qian Zhu, Xiao Zhang, Depei Wu, Zhengming Jin

Blood (2023) 142 (Supplement 1): 6238.

https://doi.org/10.1182/blood-2023-181350

Published: 2023

Journal Articles

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial

Yuankai Shi, Yan Qin, Aimin Zang, Yufu Li, Yanli Yang, Hui Liu, Sujun Gao, Xinghe Wang, Weijing Zhang, Zhengming Jin, Hui Zhou, Wang Hua-Qing, Min Wei

Blood (2022) 140 (Supplement 1): 9482–9483.

https://doi.org/10.1182/blood-2022-162984

Published: 2022

Journal Articles

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Blood (2021) 138 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2021-152927

Published: 2021

Journal Articles

Outcome of Autologous Hematopoietic Cell Transplantation in First Complete Remission(CR1) in Patients with Peripheral T-Cell Lymphomas(PTCLs)

Shuo Liu, Zhengming Jin, Depei Wu, MD PhD, Haiwen Huang, MD PhD

Blood (2019) 134 (Supplement_1): 3315.

https://doi.org/10.1182/blood-2019-125666

Published: 2019

Journal Articles

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Changju Qu, PhD, Nana Ping, MD, PhD, Danqing Kong, MD, Fan Xia, MD, Depei Wu, MD PhD, Zhengming Jin, MD

Blood (2019) 134 (Supplement_1): 5338.

https://doi.org/10.1182/blood-2019-128111

Published: 2019

Journal Articles

Outcomes of Haploidentical Haematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Haemoglobinuria

Limin Liu, MD PhD, Huifen Zhou, Miao Miao, Depei Wu, MD PhD, Xiaowen Tang, Huiying Qiu, PhD, Yue Han, MD, Zhengming Jin, MD, Suning Chen, Aining Sun, PhD, Qingyuan Wang, MD

Blood (2019) 134 (Supplement_1): 5730.

https://doi.org/10.1182/blood-2019-131808

Published: 2019

Journal Articles

Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia

Yunju Ma, Changju Qu, PhD, Haiping Dai, Jia Yin, Zheng Li, Jia Chen, Huiying Qiu, Aining Sun, PhD, Miao Miao, Chengcheng Fu, Zhengming Jin, MD, Xiaming Zhu, Depei Wu, MD PhD, Xiaowen Tang

Blood (2019) 134 (Supplement_1): 3306.

https://doi.org/10.1182/blood-2019-124033

Published: 2019

Journal Articles

Radiotherapy Priming Chimeric Antigen Receptor T Cell Therapy Is a Safe and Promising Approach in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with High Tumor Burden

Changju Qu, MD, PhD, Nana Ping, MD, PhD, Qian Wu, MD, Liqing Kang, Fan Xia, MD, Lei Yu, Depei Wu, Zhengming Jin

Blood (2018) 132 (Supplement 1): 2961.

https://doi.org/10.1182/blood-2018-99-113979

Published: 2018

Journal Articles

Possible Factors on Efficacy and Safety of CAR-T Therapy in Relapsed or Refractory Aggressive B-Cell Lymphoma

Haiwen Huang, Yibin Jiang, Zhengming Jin, Caixia Li, Depei Wu

Blood (2018) 132 (Supplement 1): 5386.

https://doi.org/10.1182/blood-2018-99-114727

Published: 2018

Journal Articles

Outcomes of Unrelated Cord Blood Transplantation for 18 Patients with Severe Aplastic Anemia

Limin Liu, Miao Miao, Huiying Qiu, PhD, XiaoWen Tang, MD, Yue Han, MD, Chengcheng Fu, Zhengming Jin, Aining Sun, PhD, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 5554.

https://doi.org/10.1182/blood.V130.Suppl_1.5554.5554

Published: 2017

Journal Articles

Modified BuCy Vs BEAM Followed By Autologous Stem Cell Transplantation in Lymphoma: Case Pair Comparative Analysis on Toxicity and Efficacy

Haiwen Huang, MD, Lihong Zhang, Yibin Jiang, Zhengming Jin, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 5525.

https://doi.org/10.1182/blood.V130.Suppl_1.5525.5525

Published: 2017

Journal Articles

Outcomes of Combination of HLA-Haploidentical Hematopoietic SCT with an Unrelated Cord Blood Unit for 127 Patients with Acquired Severe Aplastic Anemia

Miao Miao, Limin Liu, Huiying Qiu, PhD, XiaoWen Tang, MD, Yue Han, MD, Chengcheng Fu, Zhengming Jin, Aining Sun, PhD, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 4574.

https://doi.org/10.1182/blood.V130.Suppl_1.4574.4574

Published: 2017

NARROW

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Addition of Chidamide to a Sandwich Protocol, Pegaspargase, Gemcitabine and Oxaliplatin Chemotherapy Combined with Radiotherapy, As First-Line Treatment in Early Stage NK/T-Cell Lymphoma: Real World Outcomes in a Retrospective Study

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Zr Study: A Prospective Phase II Study of Zanubrutinib-Rituximab Chemo-Free Therapy with or without Autologous Stem Cell Transplantation in Newly Diagnosed Mantle Cell Lymphoma

Survival Outcome of Autologous or Allogeneic Stem Cell Transplantation in 49 Patients with Extranodal NK/T-Cell Lymphoma

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Preliminary Results from a Phase II Study

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Outcome of Autologous Hematopoietic Cell Transplantation in First Complete Remission(CR1) in Patients with Peripheral T-Cell Lymphomas(PTCLs)

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Outcomes of Haploidentical Haematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Haemoglobinuria

Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia

Radiotherapy Priming Chimeric Antigen Receptor T Cell Therapy Is a Safe and Promising Approach in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with High Tumor Burden

Possible Factors on Efficacy and Safety of CAR-T Therapy in Relapsed or Refractory Aggressive B-Cell Lymphoma

Outcomes of Unrelated Cord Blood Transplantation for 18 Patients with Severe Aplastic Anemia

Modified BuCy Vs BEAM Followed By Autologous Stem Cell Transplantation in Lymphoma: Case Pair Comparative Analysis on Toxicity and Efficacy

Outcomes of Combination of HLA-Haploidentical Hematopoietic SCT with an Unrelated Cord Blood Unit for 127 Patients with Acquired Severe Aplastic Anemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only